OCTAGON CAPITAL ADVISORS LP
Q3 2025 Form 13-F
NEW YORK, NEW YORK
CIK 0001839435
· CRD 306424
· SEC-registered investment adviser
$659.8M Reported Value Total
OCTAGON CAPITAL ADVISORS LP reports 8 total accounts under management (AUM). There are 8 discretionary accounts valued at $1,175,272,000, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
4 funds
· $1.2B gross asset value
Hedge Fund: $975.2M · Private Equity Fund: $200.1M
Source: Form ADV filed 2026-03-20
Reported value
$659.8M
Quarter over quarter
+56.7%
Holdings
26
Top-10 concentration
71.3%
Key People
Form ADV owners & control persons
Ting (nmn) Jia
FOUNDER, PORTFOLIO MANAGER, AND LIMITED PARTNER
Justin M Hirsch
CHIEF COMPLIANCE OFFICER AND CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2025 13F record
Q3 2025 13F filing summary
| Period of report | September 30, 2025 |
|---|---|
| Filed | November 14, 2025 |
| Form | 13F-HR |
| Reported value | $659.8M |
| Positions | 26 |
| Change in reported value | +44.8% |
| New positions | 4 |
| Exited positions | 8 |
| Position turnover | 35.3% |
| Top-10 concentration | 71.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
26 | $1.1B |
|
Q1 2026 13F
Filed May 15, 2026
|
29 | $903.6M |
|
Q4 2025 13F
Filed Feb 17, 2026
|
26 | $823.7M |
|
Q3 2025 13F
Filed Nov 14, 2025
|
26 | $659.8M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
30 | $455.6M |
|
Q1 2025 13F
Filed May 15, 2025
|
34 | $516.8M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
31 | $607.7M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
41 | $642.9M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
44 | $636.3M |
|
Q1 2024 13F
Filed May 15, 2024
|
56 | $834.4M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
33 | $625.0M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
35 | $650.9M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
40 | $718.7M |
|
Q1 2023 13F
Filed May 15, 2023
|
35 | $695.0M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
32 | $642.2M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
35 | $579.4M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
20 | $374.7M |
|
Q1 2022 13F
Filed May 16, 2022
|
24 | $462.6M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
28 | $513.9M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
30 | $406.1M |
3 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ABVX ABIVAX SA | $112.5M | 17.05% |
| 2 | DNTH DIANTHUS THERAPEUTICS INC | $95.1M | 14.41% |
| 3 | GOSS GOSSAMER BIO INC | $44.8M | 6.8% |
| 4 | COGT COGENT BIOSCIENCES INC | $41.3M | 6.26% |
| 5 | AVBP ARRIVENT BIOPHARMA INC | $36.4M | 5.51% |
| 6 | OCUL OCULAR THERAPEUTIX INC | $30.7M | 4.65% |
| 7 | TSHA TAYSHA GENE THERAPIES INC | $29.7M | 4.49% |
| 8 | MRUS MERUS N V | $29.0M | 4.4% |
| 9 | TRVI TREVI THERAPEUTICS INC | $25.8M | 3.9% |
| 10 | MNMD MIND MEDICINE MINDMED INC | $25.1M | 3.81% |
| 11 | APLS APELLIS PHARMACEUTICALS INC | $20.4M | 3.1% |
| 12 | KYMR KYMERA THERAPEUTICS INC | $20.4M | 3.09% |
| 13 | CNTA CENTESSA PHARMACEUTICALS PLC | $20.1M | 3.05% |
| 14 | CDTX C CIDARA THERAPEUTICS INC | $19.2M | 2.9% |
| 15 | PHVS PHARVARIS N V | $18.0M | 2.73% |
| 16 | KALV KALVISTA PHARMACEUTICALS INC | $15.5M | 2.35% |
| 17 | CRBP CORBUS PHARMACEUTICALS HLDGS | $14.1M | 2.14% |
| 18 | BBOT BRIDGEBIO ONCOLOGY THERAPEUT | $12.1M | 1.83% |
| 19 | DBVT DBV TECHNOLOGIES S A | $10.2M | 1.54% |
| 20 | NUVB NUVATION BIO INC | $9.7M | 1.48% |
Values as reported on the Q3 2025 Form 13F. Every position is in the holdings table below.